5WGP
Human Carbonic Anhydrase IX-mimic complexed with AceK
Summary for 5WGP
Entry DOI | 10.2210/pdb5wgp/pdb |
Descriptor | Carbonic anhydrase 2, ZINC ION, Acesulfame, ... (4 entities in total) |
Functional Keywords | carbonic anhydrase, acesulfame, inhibitor, lyase |
Biological source | Homo sapiens (Human) |
Cellular location | Cytoplasm : P00918 |
Total number of polymer chains | 1 |
Total formula weight | 29399.33 |
Authors | Murray, A.B.,Lomelino, C.L.,Supuran, C.T.,McKenna, R. (deposition date: 2017-07-14, release date: 2018-02-07, Last modification date: 2024-03-13) |
Primary citation | Murray, A.B.,Lomelino, C.L.,Supuran, C.T.,McKenna, R. "Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms. J. Med. Chem., 61:1176-1181, 2018 Cited by PubMed Abstract: Human carbonic anhydrase IX (CA IX) is upregulated in neoplastic tissues; as such, it is studied as a drug target for anticancer chemotherapy. Inhibition of CA IX has been shown to be therapeutically favorable in terms of reducing tumor growth. Previously, saccharin, a commonly used artificial sweetener, has been observed to selectively inhibit CA IX over other CA isoforms. In this study, X-ray crystallography showed acesulfame potassium (Ace K) binding directly to the catalytic zinc in CA IX (mimic) and through a bridging water in CA II. This modulation in binding is reflected in the binding constants, with Ace K inhibiting CA IX but not other CA isoforms. Hence, this study establishes the potential of Ace K (an FDA approved food additive) as a lead compound in the design and development of CA IX specific inhibitors. PubMed: 29266943DOI: 10.1021/acs.jmedchem.7b01470 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.53 Å) |
Structure validation
Download full validation report